Breaking News

Trials & Filings in Brief: Sept. 27, 2013

By Gil Roth | September 27, 2013

CSL Behring, Durata, Novartis, Zalicus

Filings
CSL Behring's Hizentra cleared to treat PID in Japan . . . read more

Durata files NDA for ABSSSI treatment . . . read more

Zalicus gets orphan designation for Z160 . . . read more

Post-Approval
Good data for Novartis' Lucentis . . . read more

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials